COGT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
COGT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Cogent Biosciences's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.04.
Cogent Biosciences's long-term debt to total assets ratio declined from Mar. 2023 (0.07) to Mar. 2024 (0.04). It may suggest that Cogent Biosciences is progressively becoming less dependent on debt to grow their business.
The historical data trend for Cogent Biosciences's LT-Debt-to-Total-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cogent Biosciences Annual Data | |||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||||||
LT-Debt-to-Total-Asset | Get a 7-Day Free Trial | 0.09 | 0.01 | - | 0.06 | 0.06 |
Cogent Biosciences Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
LT-Debt-to-Total-Asset | Get a 7-Day Free Trial | 0.07 | 0.05 | 0.05 | 0.06 | 0.04 |
Cogent Biosciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
LT Debt to Total Assets (A: Dec. 2023 ) | = | Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 ) | / | Total Assets (A: Dec. 2023 ) |
= | 17.467 | / | 313.437 | |
= |
Cogent Biosciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as
LT Debt to Total Assets (Q: Mar. 2024 ) | = | Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 ) | / | Total Assets (Q: Mar. 2024 ) |
= | 17.091 | / | 476.111 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cogent Biosciences (NAS:COGT) LT-Debt-to-Total-Asset Explanation
LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.
Thank you for viewing the detailed overview of Cogent Biosciences's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Fairmount Funds Management Llc | 10 percent owner, other: See Remarks | 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428 |
Evan Kearns | officer: Chief Legal Officer | AGENUS INC., 3 FORBES ROAK, LEXINGTON MA 02421 |
John L. Green | officer: Chief Financial Officer | MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139 |
John Edward Robinson | officer: Chief Scientific Officer | C/O COGENT BIOSCIENCES, INC., 200 CAMBRIDGE PARK DRIVE, SUITE 2500, CAMBRIDGE MA 02140 |
Christopher W. Cain | director | 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103 |
Peter Evan Harwin | director | 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103 |
Arlene Morris | director | C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304 |
Todd Shegog | director | 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139 |
Jessica Sachs | officer: Chief Medical Officer | C/O UNUM THERAPEUTICS INC., 200 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140 |
Matthew Ros | director | C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Karen Jean Ferrante | director | 150 ADIRONDACK DRIVE, EAST GREENWICH RI 02818 |
Andrew R Robbins | director, officer: President and CEO | C/O 3200 WALNUT ST, BOULDER CO 80301 |
Venrock Healthcare Capital Partners Iii, L.p. | 10 percent owner | 530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036 |
Vhcp Management Iii, Llc | 10 percent owner | 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018 |
Vhcp Management Ii, Llc | 10 percent owner | 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018 |
From GuruFocus
By Marketwired • 08-08-2023
By PurpleRose PurpleRose • 07-14-2022
By Value_Insider Value_Insider • 11-03-2022
By Value_Insider Value_Insider • 11-28-2022
By sperokesalga sperokesalga • 06-09-2023
By sperokesalga sperokesalga • 04-12-2023
By PurpleRose PurpleRose • 07-15-2022
By PurpleRose PurpleRose • 08-09-2022
By Value_Insider Value_Insider • 10-26-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.